ArticleMaterials letters2025
Re-direction of surface plasmon-coupled emission using metallic nanoparticles.
Article in Materials letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Fluorophores within near-field distances of thin metal films are known to be coupled with plasmonic states thereby resulting in a narrow angular distribution of emissions from the bottom of the structure. This phenomenon of surface plasmon-coupled emission (SPCE) has become widely used in immunoassays and diagnostics. The coupled emission is typically measured through a prism under the slide, which can be difficult for microplate readers and other instruments designed for rapid testing, or high-throughput screening. We show that SPCE can be re-directed upwards into the free-space direction using a layer of silver particles. This result enables fluorescence to be measured from the top or bottom of the sample. This capability may expand the range of assays using plasmon-controlled fluorescence (PCF).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.